Table 2.

Association of CTI with all-cause and CVD mortality in CKM syndrome stages 0–3

	Model 1		Model 2		Model 3
	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value
All-cause mortality
Per unit	1.32(1.23,1.41)	< 0.001	1.24(1.15,1.34)	< 0.001	1.56(1.36,1.78)	< 0.001
Per SD	1.30(1.22,1.38)	< 0.001	1.22(1.14,1.32)	< 0.001	1.51(1.33,1.72)	< 0.001
Q1	Ref		Ref		Ref
Q2	1.18(0.96,1.46)	0.12	1.19(0.94,1.50)	0.15	1.32(1.05,1.65)	0.02
Q3	1.30(1.06,1.60)	0.01	1.30(1.04,1.62)	0.02	1.52(1.23,1.88)	< 0.001
Q4	1.72(1.43,2.08)	< 0.001	1.54(1.24,1.90)	< 0.001	1.83(1.43,2.34)	< 0.001
P for trend		< 0.001		< 0.001		< 0.001
CVD mortality
Per unit	1.41(1.22,1.63)	< 0.001	1.35(1.15,1.58)	< 0.001	2.03(1.49,2.77)	< 0.001
Per SD	1.38(1.20,1.58)	< 0.001	1.32(1.14,1.53)	< 0.001	1.94(1.45,2.59)	< 0.001
Q1	Ref		Ref		Ref
Q2	1.22(0.84,1.78)	0.30	1.30(0.83,2.01)	0.25	1.55(0.99,2.43)	0.06
Q3	1.69(1.19,2.40)	0.003	1.79(1.17,2.73)	0.01	2.35(1.45,3.81)	< 0.001
Q4	1.86(1.27,2.73)	0.001	1.82(1.17,2.84)	0.01	2.64(1.55,4.47)	< 0.001
P for trend		< 0.001		0.004		< 0.001

Model 1: adjusted for age, sex, and race

Model 2: further adjusted for marital status, education level, family poverty-income ratio, smoking status, alcohol use, BMI, and HEI score

Model 3: further adjusted for HbA1c, TC, HDL, LDL, serum uric acid, eGFR, drugs for hypertension, hyperlipidemia, diabetes